DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Fixed Dose Combination of Bisoprolol and Amlodipine in the Treatment of Hypertension

Information source: Merck KGaA
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Hypertension

Intervention: Bisoprolol/Amlodipine (Bisoprolol sub-group A) (Drug); Bisoprolol/Amlodipine (Bisoprolol sub-group B) (Drug); Bisoprolol/Amlodipine (Amlodipine sub-group A) (Drug); Bisoprolol/Amlodipine (Amlodipine sub-group B) (Drug)

Phase: Phase 3

Status: Completed

Sponsored by: Merck KGaA

Official(s) and/or principal investigator(s):
Regional medical director LATAM, Study Director, Affiliation: Merck S.A., Brazil, an affiliate of Merck KGaA, Darmstadt, Germany

Summary

This is a randomized, comparative Phase 3 trial to investigate the efficacy of fixed dose combination (FDC) of bisoprolol and amlodipine in hypertensive subjects.

Clinical Details

Official title: A Randomized, Comparative Trial of Concor AM, a Fixed Dose Combination of Bisoprolol and Amlodipine, on the Treatment of Essential Hypertensive Patients Whose Blood Pressure is Not Well Controlled by Monotherapy of Bisoprolol 5mg or Amlodipine 5mg

Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment

Primary outcome: Mean reduction of systolic blood pressure (SBP) after 18 weeks of treatment from Baseline (latest SBP before study treatment)

Secondary outcome:

Change from Baseline (latest diastolic blood pressure [DBP] before study treatment) in DBP after 18 weeks of treatment

Percentage of subjects with controlled blood pressure under different dosages of after study treatment

Change from Baseline (latest heart rate [HR] before study treatment) in HR after 18 weeks treatment

Number of subjects with adverse events (AEs)

Eligibility

Minimum age: 18 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Essential hypertension not controlled at 5 mg bisoprolol or 5 mg amlodipine at least

12 weeks (definition of not controlled: SBP greater than or equal to (>=) 140 millimeter of mercury (mmHg) with or without DBP >= 90 mmHg)

- Male or female subjects >=18 years of age, without limitation on race

- Medically accepted effective contraception if procreative potential exists

(applicable for both male and female subjects until at least 90 days after the last dose of trial treatment)

- Subjects who have signed the informed consent form before any trial related

assessment Exclusion Criteria:

- General contraindications of beta-blockers and/or calcium channel blockers

- Previous and concurrent acute heart failure or during episodes of heart failure

decompensation requiring intravenous inotropic therapy

- Concurrent cardiogenic shock

- Previous and concurrent second or third degree atrioventricular (AV) block

(without a pacemaker)

- Previous and concurrent sick sinus syndrome

- Previous and concurrent sinoatrial block

- Concurrent symptomatic bradycardia

- Concurrent symptomatic hypotension

- Previous and concurrent severe bronchial asthma or chronic obstructive pulmonary

diseases

- Previous and concurrent severe peripheral arterial occlusive diseases and

Raynaud's syndrome

- Untreated pheochromocytoma

- Concurrent metabolic acidosis

- Known hypersensitivity to bisoprolol, amlodipine, dihydropyridine derivates or

to any of the excipients

- Seated pulse rate less than 60 beats per minute (bpm) at screening

- Any other anti-hypertensive drugs (other than bisoprolol and amlodipine) are used

within 4 weeks prior to the screening visit

- Use of any enzyme-modifying drugs acting on cytochrome P450 (CYP) 3A4 enzymes via

inhibition (such as ketoconazole, itraconazole, ritonavir) or induction (such as rifampicin or hypericum perforatum) within 28 days before Day 1 of the trial

- Other significant disease that in the Investigator's opinion that would exclude the

subject from the trial, such as uncontrolled diabetes mellitus, severe liver and/or kidney dysfunction, decompensated cardiac failure

- Any other condition or therapy which in the Investigator's opinion would pose a risk

to the subject or interfere with the trial objectives

- Concurrent alcohol and/or drug abuse

- Known hypersensitivity to the trial treatments

- Pregnancy and lactation period. All female subjects with reproductive potential must

have a negative pregnancy serum test within the 7 days prior to enrollment

- Known lack of subject compliance

- Legal incapacity or limited legal capacity

- Participation in another clinical trial within the previous 30 days

- Persons directly involved in the execution of the protocol

Locations and Contacts

Please contact the Merck KGaA Communication Center located in, Darmstadt, Germany
Additional Information

Starting date: March 2014
Last updated: June 18, 2015

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017